Univariate and multivariate linear regression analysis of factors affecting AUC of CMV viral load in the first year posttransplant
| Univariate . | . | . | . |
|---|---|---|---|
| Covariate . | Category . | AUC mean difference∗ (95% CI) . | P . |
| GVHD prevention method | MTX | 1 | |
| MMF | 0.125 (0.061-0.189) | <.001 | |
| PTCy | 0.016 (−0.126 to 0.158) | .827 | |
| Donor relationship | Sibling | 1 | |
| Unrelated | 0.148 (0.085-0.211) | <.001 | |
| Donor CMV serostatus | − | 1 | |
| + | −0.069 (−0.132 to −0.007) | .03 | |
| Conditioning regimen | Nonmyeloablative | 1 | |
| Myeloablative | −0.123 (−0.188 to −0.059) | <.001 | |
| RIC | −0.018 (−0.145 to 0.109) | .782 | |
| Recipient age at transplant | As continuous | 0.003 (0.001-0.006) | .003 |
| Donor age at transplant | As continuous | −0.003 (−0.005 to −0.001) | .001 |
| Univariate . | . | . | . |
|---|---|---|---|
| Covariate . | Category . | AUC mean difference∗ (95% CI) . | P . |
| GVHD prevention method | MTX | 1 | |
| MMF | 0.125 (0.061-0.189) | <.001 | |
| PTCy | 0.016 (−0.126 to 0.158) | .827 | |
| Donor relationship | Sibling | 1 | |
| Unrelated | 0.148 (0.085-0.211) | <.001 | |
| Donor CMV serostatus | − | 1 | |
| + | −0.069 (−0.132 to −0.007) | .03 | |
| Conditioning regimen | Nonmyeloablative | 1 | |
| Myeloablative | −0.123 (−0.188 to −0.059) | <.001 | |
| RIC | −0.018 (−0.145 to 0.109) | .782 | |
| Recipient age at transplant | As continuous | 0.003 (0.001-0.006) | .003 |
| Donor age at transplant | As continuous | −0.003 (−0.005 to −0.001) | .001 |
| Multivariate . | . | . | . |
|---|---|---|---|
| Covariate . | Category . | AUC mean difference∗ (95% CI) . | P . |
| GVHD prevention method | MTX | 1 | |
| MMF | 0.087 (−0.019 to 0.193) | .106 | |
| PTCy | −0.005 (−0.146 to 0.137) | .947 | |
| Donor relationship | Sibling | 1 | |
| Unrelated | 0.103 (0.014-0.192) | .023 | |
| Donor CMV serostatus | − | 1 | |
| + | −0.027 (−0.091 to 0.037) | .406 | |
| Conditioning regimen | Nonmyeloablative | 1 | |
| Myeloablative | −0.026 (−0.135 to 0.082) | .636 | |
| RIC | −0.006 (−0.138 to 0.127) | .933 | |
| Donor age at transplant | As continuous | −0.002 (−0.005 to 0.001) | .236 |
| Recipient age at transplant | As continuous | 0.002 (−0.001 to 0.005) | .136 |
| Multivariate . | . | . | . |
|---|---|---|---|
| Covariate . | Category . | AUC mean difference∗ (95% CI) . | P . |
| GVHD prevention method | MTX | 1 | |
| MMF | 0.087 (−0.019 to 0.193) | .106 | |
| PTCy | −0.005 (−0.146 to 0.137) | .947 | |
| Donor relationship | Sibling | 1 | |
| Unrelated | 0.103 (0.014-0.192) | .023 | |
| Donor CMV serostatus | − | 1 | |
| + | −0.027 (−0.091 to 0.037) | .406 | |
| Conditioning regimen | Nonmyeloablative | 1 | |
| Myeloablative | −0.026 (−0.135 to 0.082) | .636 | |
| RIC | −0.006 (−0.138 to 0.127) | .933 | |
| Donor age at transplant | As continuous | −0.002 (−0.005 to 0.001) | .236 |
| Recipient age at transplant | As continuous | 0.002 (−0.001 to 0.005) | .136 |
Positive value for mean difference indicates absolute higher viral load AUC compared with the reference (MTX) group, whereas a negative value indicates absolute lower viral load AUC.